SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a major talking point due to an intense short squeeze, fueled by its low float and high borrow rates. The community is actively discussing its massive recent gains, drawing comparisons to past market-moving squeezes and debating the sustainability of its remarkable rally following recent business agreements.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc. is experiencing a notable stock surge and high trading volume, with community discussion intensely focused on potential catalysts like an imminent buyout or partnership despite the absence of official news. Investors are highlighting Pemvidutide's FDA Breakthrough Therapy Designation for MASH and its differentiated profile in the competitive obesity and liver disease sectors, while a vocal skeptical faction dismisses the rally as a "pump and dump."

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies (QCLS) is trending following the appointment of an OpenAI expert to its board and continued involvement from Martin Shkreli, signaling a significant pivot into quantum-class computing and AI infrastructure. The community is keenly discussing the potential for a short squeeze, drawing parallels to other recent market movers, while debating if its current market valuation reflects its innovative photonic computing technology. This strategic shift has fueled both excitement and skepticism about QCLS becoming a legitimate player in the rapidly evolving quantum sector.

BitGo Holdings, Inc. provides cryptocurrency custody solutions. It offers self-custody wallet, qualified custody, liquidity and prime, and infrastructure-as-a-service. The company was founded by Michael Belshe in 2013 and is headquartered in Palo Alto, CA.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo is trending after its recent NYSE debut saw significant initial volatility and a notable price decline, sparking a highly polarized community discussion. Many are calling it a "busted IPO" and comparing it to other underperforming crypto ventures, while bullish investors highlight its profitable business model, regulatory advantages as a federally chartered bank, and unique position in crypto infrastructure. The active debate centers on whether the stock will stabilize and rebound, with some anticipating a short squeeze against its current valuation.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending after US deep-sea mining regulations were updated by NOAA, enabling the company to file a consolidated application for exploration and recovery permits that significantly expands its operational area. The community is actively discussing the potential for rapid government approval, driven by national security interests in securing critical mineral supply chains, with many anticipating substantial upside. However, critics continue to raise concerns about environmental impacts and long-term economic viability amidst ongoing regulatory processes.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is generating significant buzz and experiencing high volatility as its Q2 earnings report approaches on February 5th, with the community largely interpreting the accelerated date as a bullish signal. Investors are actively discussing the company's strategic pivot to AI infrastructure, anticipating potential new hyperscaler deals, while some market participants highlight its extreme price swings and ongoing correlation to Bitcoin's performance.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is trending amidst heightened activity in the critical minerals sector, following its strategic acquisition of a key flotation facility vital for integrated production. The community is actively discussing recent significant institutional investments, including the State of Alaska's purchase, and eagerly anticipating potential government partnerships. This momentum reinforces UAMY's crucial role as the only integrated antimony producer supporting U.S. defense needs, reflecting a growing geopolitical focus on securing essential material supply chains.

ShapeShift is a decentralized, multichain cryptocurrency platform that empowers users to swap, track, buy, and earn with over 30,000 assets across the top blockchains such as Bitcoin, Ethereum, Dogecoin, Cosmos, and more. The platform emphasizes financial sovereignty and self-custody, providing an open-source environment where users can engage with the most popular crypto tools and services to trade, earn, and hodl their digital assets. FOX token holders can submit and vote on proposals, helping to shape the future of ShapeShift.

ShapeShift FOX Token

ShapeShift FOX Token is trending with a highly polarized community anticipating an imminent breakout from a long-term downtrend, fueled by expectations of a broader 'alt season.' Proponents emphasize its low market cap and strong DeFi fundamentals, often comparing its potential to larger decentralized exchanges for significant upside. Conversely, a frustrated segment views it as a 'pump and dump' token that consistently fails to hold gains, with some even suggesting its movements can signal bearish shifts for the wider crypto market.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific (CORZ) is heavily discussed as CoreWeave (CRWV) reported data center delays and cut revenue forecasts, with many attributing these issues directly to CORZ's execution. This situation fuels widespread community debate over the earlier rejection of CRWV's acquisition offer, leading to investor concerns about CORZ's operational capacity and future valuation as an AI infrastructure provider, despite some still seeing long-term potential in its power assets.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending following its announcement of a substantial 10-year colocation agreement with Nscale Global, valued at approximately $865 million, for its NC-1 AI data center campus. This significant contract has ignited considerable community discussion, with many investors anticipating a potential short squeeze and highlighting the company's perceived undervaluation in a high-demand AI infrastructure market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AC Immune (NASDAQ:ACIU) Stock Price Down 5.4% - Time to Sell?

AC Immune (NASDAQ:ACIU) Trading Down 5.4% - Here's Why...

Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4%

AC Immune (NASDAQ:ACIU - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227...

AC Immune (NASDAQ:ACIU) Trading Up 5% - Should You Buy?

AC Immune (NASDAQ:ACIU) Trading 5% Higher - Here's What Happened...

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...

FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ACIU News

ACIUAC Immune SA